SCIENTIFIC PROGRAM DAY ONE
7:00 am Check In, Morning Coffee & Refreshments
7:55 am Chair’s Opening Remarks
Moving the Needle Forward in 2024 & Beyond: What are the Next ADCs to Re-Shape the Field?
8:00 am Panel Discussion: Contextualizing the Ongoing Growth & Success of the ADC Field & Envisioning the Best Route Forward for ADC Innovation
Synopsis
- Reflecting on the past and envisioning the future of the ADC field: spanning upcoming approvals, exciting targets, novel linker-payloads, conjugation technologies, and combination therapies
- Deep-diving into recent clinical trials – what ADCs have broken the perceived clinical expectations for success?
- Debating rationale of going after new targets and using novel payloads against iteratively improving the validated successes in the field – what are predictions for the next ADC breakthrough?
- Diversifying your ADC portfolio across indications, targets, and ADC components to be on top of the next wave of ADC innovation
9:00 am From IND to Long Term Commercial Supply: a Step Ahead Against the Challenges of the Bioconjugates
Synopsis
- Exploring a sustainable business model
- Discussing expertise, technology and integration of services
- Examining capacity shortage challenges: what it means going forward?
9:30 am TROP2 ADC Development: Exploring the Datopotamab Deruxtecan Mechanism, Clinical Efficacy, & Future Directions
Synopsis
- Delving into the intricacies of Dato-DXd mechanism of action and the innovative approach in developing ADCs with the DXd linker-payload technology
- Examining the comprehensive late-stage clinical data for Dato-DXd, highlighting its clinical efficacy and safety profile
- Discussing the critical insights gained from the development of Dato-DXd, and outline the strategic next steps for its clinical application and further development
10:00 am Morning Break & Networking
Synopsis
As the ADC community is reunited all under one roof at the world’s leading and biggest industry forum, use this valuable time to reconnect with your peers, meet fresh faces, and visit exhibitor booths to make new and lasting scientific and business “linkers” with the wide range of attendees. This is a dedicated time to have face-to-face interaction with many of the brightest minds working in the ADC field and establish meaningful relationships – don’t forget to enjoy some refreshments before we split off into the six conference tracks.
Discovery Chemistry
Chair: Thomas Nittoli, Senior Director, Regeneron
Download the Full Event Guide for full details
Optimizing the Classics & Exploring Next Generation ADC Payloads to Guide ADC Chemistry & Design
11.00 am Evaluating Design & Optimization of Novel Exatecanbased Payloads
Paul Hogg, Vice President, Medicinal & Protein Chemistry, ADC Therapeutics
11.30 am Improved Efficacy & Reduced Toxicity of ADCs With OHPAS Linker, PMT, & Nexatecan
Yosup Rew, Chief Technology Officer, IntoCell
12.00 pm Introduction to Radioconjugates & the Promise of Theranostics for the Delivery of Molecularly Targeted Radiation
Frank Comer, Director, Tumor Targeted Delivery, Early Oncology Discovery, AstraZeneca
12.30 pm Development of a Site Specific & Versatile Conjugation Approach Based on Bacterial Transglutaminase & the Diels-Alder Cycloaddition Reaction
Francisco Velasquez, Senior Director, Chemistry, Abzena
1.00 pm Lunch & Learn Presented By Millipore Sigma
Leveraging Novel Conjugation Chemistries for Site-Specific Conjugation
2.00 pm Highlighting Novel Conjugation Technologies Spearheading the Transition Away From Stochastic Conjugation
Sayumi Yamazoe, Associate Director, ADC Discovery, Bristol Myers Squibb
2.30 pm Leveraging Cell-Free Protein Synthesis for SiteSpecific Conjugation to Enhance ADC Therapeutic Index
Gang Yin, Vice President, Research, Sutro Biopharma
3.00 pm Targeting TYRP-1 in Malignant Melanoma: Novel mavg-MMAU Linker-Payload Improves Both Efficacy & Tolerability of Auristatin ADCs
Juhani Saarinen, Chief Executive Officer, Glykos Finland Oy
3:30 pm
Afternoon Break & Technology Slam
By Beacon, Quantum Si, Sony
Synopsis
As you enjoy your afternoon refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently
What Makes a Clinically Effective ADC? Breaking Down Recent ADC Clinical Performance>
4:30 pm Technical Excellence in Development and Manufacturing of BioConjugates
Synopsis
- Introduction of the techniques used during development to achieve deep process understanding and right first time transfer to Manufacturing
- Explore the established roadmap to scale up at an experienced ADC manufacturer
- Learn through case studies : seamless transfers from process and analytical development to GMP production
5:00 pm Exploring Learnings From Translational & Clinical Development of Dolaflexin & Dolasynthen ADCs
Synopsis
- Contrasting and sharing pre-clinical and clinical data for Dolaflexin and Dolasynthen ADCs, employing the same payload and same antibody
- Predicting and evaluating differences in clinical efficacy and tolerability performance based on preclinical data – what are the core lessons?
- Breaking down how differences in ADC design impact clinical performance
5:30 pm Accelerating Novel ADC Development through WuXi XDC’s Innovative Technology & Integrated Development/Manufacturing Platform
Synopsis
- Learning how 5 of 13 approved ADCs use random cysteine conjugation with MMAE, capped at 2 mg/kg to avoid TEAEs
- Discussing how WuXiDAR4's proprietary technology creates ADCs with a narrowly distributed DAR for enhanced efficacy and safety, eliminating the need to modify monoclonal antibodies or any enzymes, simplifying the process and reducing costs of goods
- Outlining how WuXi XDC CDMO platform integrates the development and manufacturing of monoclonal antibody intermediates, payload linkers, conjugation, and drug products, expediting development from DNA to IND in under 15 months with over 60 successful IND submissions
- Leveraging deep expertise and comprehensive manufacturing, WuXi XDC offers a clear strategy to secure successful BLA filings for its clients
6:00 pm Reflecting On Phase I Termination of DHES0815A: What Were the Core Lessons Learned?
Synopsis
- Breaking down ADC design, preclinical development, and phase I clinical trial results
- What were the main takeaways from observed clinical toxicities?
- Striving for transparency on ADC clinical trial results regardless of outcome
6:30 pm Chair’s Closing Remarks
6:30 pm
Scientific Poster Session & Drinks Reception
Hosted by AsymBio
Synopsis
This is a great opportunity to showcase your latest work and get face-to-face time with attending audience of ADC experts, as well as finding out insights from ongoing ADC development by your peers. In an informal setting, you will be able to discuss, debate, and display your work in the field while enjoying a drink of your choice at our dedicated drinks reception.
7:30 pm End of Scientific Program Day One
